Skip to main content

Table 1 Demographic and clinical characteristics of the patients with G-NENs (n = 135)

From: Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience

Variables NET G1 (n = 39, %) NET G2 (n = 7, %) NEC G3 (n = 69, %) MANEC (n = 20, %) P value
Gender      <0.001
 Male 19 (48.7) 5 (71.4) 54 (78.3) 20 (100.0)  
 Female 20 (51.3) 2 (28.6) 15 (21.7) 0 (0.0)  
Age, y 53.3 ± 13.0 47.0 ± 13.1 61.0 ± 10.3 62.2 ± 10.5 <0.001
Lesion diameter, cm 1.2 ± 0.9 2.4 ± 1.8 5.2 ± 1.8 4.7 ± 3.1 <0.001
Hospital stay, days 10.7 ± 4.9 14.9 ± 5.6 16.0 ± 5.0 17.1 ± 5.5 <0.001
Tumor location      <0.001
 U 7 (17.9) 2 (28.6) 36 (52.2) 9 (45.0)  
 M 29 (74.4) 3 (42.9) 11 (15.9) 2 (10.0)  
 L 3 (7.7) 2 (28.6) 22 (31.9) 9 (45.0)  
Number of lesions      0.245
 Multiple 8 (20.5) 1 (14.3) 1 (1.4) 0 (0.0)  
 single 31 (79.5) 6 (85.7) 68 (98.6) 20 (100.0)  
Mucosal ulcer      <0.001
 Present 10 (25.6) 7 (100.0) 68 (98.6) 19 (95.0)  
 Absent 29 (74.4) 0 (0.0) 1 (1.4) 1 (5.0)  
Co-morbidity*      0.042
 Present 5 (12.8) 2 (28.6) 14 (20.3) 9 (45.0)  
 Absent 34 (87.2) 5 (71.4) 55 (79.7) 11 (55.0)  
Anemia      0.643
 Yes 5 (12.8) 2 (28.6) 9 (13.0) 3 (15.0)  
 No 34 (87.2) 5 (71.4) 60 (87.0) 17 (85.0)  
Hemoglobin level, g/L 127.8 ± 20.5 113.0 ± 20.6 124.1 ± 25.5 126.0 ± 20.3 0.463
NLR 2.5 ± 1.5 2.3 ± 1.6 3.0 ± 1.2 3.1 ± 2.1 0.197
A/G ratio 1.5 ± 0.3 1.5 ± 0.2 1.5 ± 0.3 1.6 ± 0.3 0.581
Tumor markers
 CEA↑ 2 (5.1) 0 (0.0) 13 (18.8) 3 (15.0) 0.194
 AFP↑ 0 (0.0) 0 (0.0) 3 (4.3) 0 (0.0) 0.638
 CA19-9↑ 1 (2.6) 0 (0.0) 8 (11.6) 2 (10.0) 0.354
 CA125↑ 1 (2.6) 0 (0.0) 2 (2.9) 0 (0.0) 1.000
 CA72-4↑ 0 (0.0) 0 (0.0) 2 (2.9) 2 (10.0) 0.217
  1. G-NENs gastric neuroendocrine neoplasms, NET G1 neuroendocrine tumor G1, NET G2 neuroendocrine tumor G2, NEC G3 neuroendocrine carcinoma G3, MANEC mixed adenoneuroendocrine carcinoma, U upper third of stomach, M middle third of stomach, L lower third of stomach; Co-morbidity* including diabetes mellitus, chronic pulmonary disease, cardiovascular, chronic liver and renal disease; NLR Neutrophil-Lymphocyte Ratio, A/G ratio albumin/globulin ratio, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, CA19-9 carbohydrate antigen 19-9, CA125 cancer antigen 125, CA72-4 cancer antigen 72-4